Research Analysts’ Recent Ratings Changes for Insulet (PODD)

Several brokerages have updated their recommendations and price targets on shares of Insulet (NASDAQ: PODD) in the last few weeks:

• 7/28/2026 – Insulet was downgraded by UBS Group AG from “buy” to “neutral”. They now have a $174.00 price target on the stock.
• 7/28/2026 – Insulet is now covered by UBS Group AG. They set a “neutral” rating and a $174.00 price target on the stock.
• 7/13/2026 – Insulet had its price target lowered by Truist Financial Corporation from $219.00 to $210.00. They now have a “buy” rating on the stock.
• 7/13/2026 – Insulet had its price target lowered by Royal Bank Of Canada from $280.00 to $245.00. They now have an “outperform” rating on the stock.
• 7/10/2026 – Insulet had its price target lowered by Stifel Nicolaus from $250.00 to $225.00. They now have a “buy” rating on the stock.
• 7/8/2026 – Insulet had its price target raised by Citigroup Inc. from $165.00 to $172.00. They now have a “neutral” rating on the stock.
• 7/6/2026 – Insulet was given a new $180.00 price target by Evercore Inc.
• 6/27/2026 – Insulet was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 6/24/2026 – Insulet was downgraded by Weiss Ratings from “hold (c-)” to “sell (d+)”.
• 6/23/2026 – Insulet is now covered by Deutsche Bank Aktiengesellschaft. They set a “buy” rating and a $190.00 price target on the stock.
• 6/11/2026 – Insulet was given a new $219.00 price target by UBS Group AG.
• 6/11/2026 – Insulet had its price target lowered by Truist Financial Corporation from $250.00 to $219.00. They now have a “buy” rating on the stock.
• 6/8/2026 – Insulet was given a new $216.00 price target by Raymond James Financial, Inc..
• 6/1/2026 – Insulet had its price target lowered by TD Cowen from $379.00 to $294.00. They now have a “hold” rating on the stock.

Insider Buying and Selling

In other news, Director Timothy C. Stonesifer bought 2,790 shares of the firm’s stock in a transaction on Wednesday, June 3rd. The shares were bought at an average cost of $143.51 per share, for a total transaction of $400,392.90. Following the acquisition, the director directly owned 9,041 shares of the company’s stock, valued at $1,297,473.91. This trade represents a 44.63% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. 0.36% of the stock is owned by company insiders.

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.